

Income statement

Three months ended 30th September 2008

	Business performance £m	Restruct- uring £m	Total £m	Business performance \$m	Restruct- uring \$m	Total \$m
Turnover:						
Pharmaceuticals	4,888	-	4,888	9,144	-	9,144
Consumer healthcare	994	-	994	1,864	-	1,864
TURNOVER	5,882	-	5,882	11,008	-	11,008
Cost of sales	(1,460)	(130)	(1,590)	(2,740)	(246)	(2,986)
Gross profit	4,422	(130)	4,292	8,268	(246)	8,022
Selling, general and administration	(1,662)	(157)	(1,819)	(3,102)	(304)	(3,406)
Research and development	(834)	(35)	(869)	(1,563)	(67)	(1,630)
Other operating income	53	-	53	89	-	89
Operating profit:						
Pharmaceuticals	1,755	(311)	1,444	3,268	(596)	2,672
Consumer healthcare	224	(11)	213	424	(21)	403
OPERATING PROFIT	1,979	(322)	1,657	3,692	(617)	3,075
Finance income	98	-	98	184	-	184
Finance expense	(218)	-	(218)	(410)	-	(410)
Share of after tax profits of joint ventures and associates	16	-	16	31	-	31
PROFIT BEFORE TAXATION	1,875	(322)	1,553	3,497	(617)	2,880
Taxation	(559)	62	(497)	(1,044)	118	(926)
PROFIT AFTER TAXATION FOR THE PERIOD	1,316	(260)	1,056	2,453	(499)	1,954
Profit attributable to minority interests	29	-	29	55	-	55
Profit attributable to shareholders	1,287	(260)	1,027	2,398	(499)	1,899
	1,316	(260)	1,056	2,453	(499)	1,954
EARNINGS PER SHARE	25.2p		20.1p	47.1¢		37.6¢
Diluted earnings per share	25.0p		20.0p	46.8¢		37.4¢

US dollar amounts shown above are a convenience translation of the sterling amounts.

Income statement

Nine months ended 30th September 2008

	Business performance £m	Restruct- uring £m	Total £m	Business performance \$m	Restruct- uring \$m	Total \$m
Turnover:						
Pharmaceuticals	14,578	-	14,578	28,427	-	28,427
Consumer Healthcare	2,864	-	2,864	5,585	-	5,585
TURNOVER	17,442	-	17,442	34,012	-	34,012
Cost of sales	(4,134)	(328)	(4,462)	(8,062)	(640)	(8,702)
Gross profit	13,308	(328)	12,980	25,950	(640)	25,310
Selling, general and administration	(5,147)	(213)	(5,360)	(10,037)	(415)	(10,452)
Research and development	(2,416)	(53)	(2,469)	(4,711)	(103)	(4,814)
Other operating income	408	-	408	796	-	796
Operating profit:						
Pharmaceuticals	5,609	(581)	5,028	10,937	(1,133)	9,804
Consumer Healthcare	544	(13)	531	1,061	(25)	1,036
OPERATING PROFIT	6,153	(594)	5,559	11,998	(1,158)	10,840
Finance income	276	-	276	538	-	538
Finance expense	(600)	(2)	(602)	(1,170)	(4)	(1,174)
Share of after tax profits of joint ventures and associates	30	-	30	59	-	59
PROFIT BEFORE TAXATION	5,859	(596)	5,263	11,425	(1,162)	10,263
Taxation	(1,699)	131	(1,568)	(3,313)	255	(3,058)
PROFIT AFTER TAXATION FOR THE PERIOD	4,160	(465)	3,695	8,112	(907)	7,205
Profit attributable to minority interests	75	-	75	146	-	146
Profit attributable to shareholders	4,085	(465)	3,620	7,966	(907)	7,059
	4,160	(465)	3,695	8,112	(907)	7,205
EARNINGS PER SHARE	78.0p		69.2p	152.1¢		134.9¢
Diluted earnings per share	77.5p		68.7p	151.1¢		134.0¢

US dollar amounts shown above are a convenience translation of the sterling amounts.

Turnover

Pharmaceuticals including vaccines Three months ended 30th September 2008

	Total £m	USA £m	Europe £m	ROW £m	Total \$m	USA \$m	Europe \$m	ROW \$m
Respiratory	1,348	636	449	263	2,519	1,191	836	492
<i>Seretide/Advair</i>	982	515	324	143	1,838	966	604	268
<i>Flixotide/Flovent</i>	149	71	38	40	278	132	71	75
<i>Serevent</i>	60	17	32	11	111	31	60	20
<i>Veramyst</i>	17	12	3	2	32	22	6	4
<i>Flixonase/Flonase</i>	33	7	11	15	60	12	20	28
Anti-virals	792	398	199	195	1,485	748	371	366
HIV	377	153	150	74	706	287	279	140
<i>Epzicom/Kivexa</i>	110	44	50	16	206	83	93	30
<i>Combivir</i>	110	41	38	31	206	77	71	58
<i>Trizivir</i>	49	24	22	3	91	45	40	6
<i>Agenerase, Lexiva</i>	40	21	15	4	75	40	28	7
<i>Epivir</i>	35	11	13	11	66	20	25	21
<i>Ziagen</i>	27	10	8	9	51	19	15	17
<i>Valtrex</i>	303	223	35	45	570	420	66	84
<i>Zeffix</i>	42	4	7	31	78	7	13	58
<i>Relenza</i>	12	5	-	7	22	9	-	13
Central nervous system	585	321	142	122	1,075	581	266	228
<i>Lamictal</i>	136	84	37	15	241	143	70	28
<i>Imigran/Imitrex</i>	188	154	24	10	353	290	44	19
<i>Seroxat/Paxil</i>	112	13	27	72	208	23	51	134
<i>Wellbutrin</i>	53	44	6	3	94	77	11	6
<i>Requip</i>	56	13	35	8	104	23	66	15
<i>Requip XL</i>	15	4	11	-	29	8	21	-
<i>Treximet</i>	4	4	-	-	7	7	-	-
Cardiovascular and urogenital	466	280	130	56	875	527	243	105
<i>Avodart</i>	102	63	29	10	192	118	55	19
<i>Lovaza</i>	75	75	-	-	141	141	-	-
<i>Coreg</i>	50	49	-	1	94	92	-	2
<i>Coreg CR</i>	41	41	-	-	77	77	-	-
<i>Coreg IR</i>	9	8	-	1	17	15	-	2
<i>Fraxiparine</i>	59	-	47	12	111	-	89	22
<i>Arixtra</i>	44	22	19	3	83	42	35	6
<i>Vesicare</i>	18	18	-	-	34	34	-	-
<i>Levitra</i>	16	15	1	-	30	28	2	-
Metabolic	289	136	72	81	542	255	135	152
<i>Avandia products</i>	191	99	48	44	357	185	89	83
<i>Avandia</i>	118	67	20	31	220	125	37	58
<i>Avandamet</i>	63	26	26	11	118	48	49	21
<i>Bonviva/Boniva</i>	56	36	18	2	105	68	33	4
Anti-bacterials	340	40	141	159	635	75	262	298
<i>Augmentin</i>	143	9	62	72	268	17	116	135
<i>Altabax</i>	5	4	1	-	9	7	2	-
Oncology and emesis	128	64	41	23	240	120	77	43
<i>Hycamtin</i>	34	20	12	2	64	38	22	4
<i>Zofran</i>	33	6	15	12	62	11	29	22
<i>Tykerb</i>	26	12	10	4	49	22	19	8
Vaccines	730	218	323	189	1,383	416	611	356
<i>Hepatitis</i>	174	82	61	31	327	155	114	58
<i>Infanrix/Pediarix</i>	168	56	89	23	315	105	167	43
<i>Fluarix, FluLaval</i>	144	63	58	23	281	123	113	45
<i>Flu-prepandemic</i>	10	-	10	-	18	-	18	-
<i>Cervarix</i>	43	-	38	5	83	-	73	10
<i>Rotarix</i>	39	4	11	24	74	8	20	46
<i>Boostrix</i>	22	13	7	2	41	24	13	4
Other	210	8	66	136	390	15	123	252
	4,888	2,101	1,563	1,224	9,144	3,928	2,924	2,292

Pharmaceutical turnover includes co-promotion income. US dollar amounts shown above are a convenience translation of the sterling amounts.

Turnover

Pharmaceuticals including vaccines Nine months ended 30th September 2008

	Total £m	USA £m	Europe £m	ROW £m	Total \$m	USA \$m	Europe \$m	ROW \$m
Respiratory	4,086	1,868	1,432	786	7,968	3,643	2,792	1,533
<i>Seretide/Advair</i>	2,900	1,487	1,024	389	5,655	2,900	1,997	758
<i>Flixotide/Flovent</i>	469	214	125	130	915	417	244	254
<i>Serevent</i>	193	50	103	40	376	97	201	78
<i>Veramyst</i>	47	38	5	4	92	74	10	8
<i>Flixonase/Flonase</i>	144	44	40	60	281	86	78	117
Anti-virals	2,282	1,100	626	556	4,450	2,145	1,221	1,084
HIV	1,096	447	471	178	2,137	872	918	347
<i>Epzicom/Kivexa</i>	313	123	152	38	610	240	296	74
<i>Combivir</i>	319	127	124	68	622	248	242	132
<i>Trizivir</i>	153	74	70	9	298	144	136	18
<i>Agenerase, Lexiva</i>	113	57	46	10	220	111	90	19
<i>Epivir</i>	103	33	43	27	201	64	84	53
<i>Ziagen</i>	78	31	27	20	152	60	53	39
<i>Valtrex</i>	829	591	106	132	1,617	1,153	207	257
<i>Zeffix</i>	135	11	20	104	263	21	39	203
<i>Relenza</i>	44	15	1	28	86	29	2	55
Central nervous system	2,232	1,462	414	356	4,352	2,851	807	694
<i>Lamictal</i>	749	592	108	49	1,461	1,154	211	96
<i>Imigran/Imitrex</i>	526	427	71	28	1,026	833	138	55
<i>Seroxat/Paxil</i>	360	60	86	214	702	117	168	417
<i>Wellbutrin</i>	276	254	12	10	538	495	23	20
<i>Requip</i>	208	91	95	22	406	178	185	43
<i>Requip XL</i>	23	4	19	-	45	8	37	-
<i>Treximet</i>	12	12	-	-	23	23	-	-
Cardiovascular and urogenital	1,299	763	375	161	2,533	1,488	731	314
<i>Avodart</i>	279	167	85	27	544	325	166	53
<i>Lovaza</i>	192	191	-	1	374	372	-	2
<i>Coreg</i>	142	140	-	2	277	273	-	4
<i>Coreg CR</i>	115	114	-	1	224	222	-	2
<i>Coreg IR</i>	27	26	-	1	53	51	-	2
<i>Fraxiparine</i>	168	-	134	34	328	-	262	66
<i>Arixtra</i>	115	57	50	8	224	111	97	16
<i>Vesicare</i>	48	48	-	-	94	94	-	-
<i>Levitra</i>	43	41	2	-	84	80	4	-
Metabolic	846	408	218	220	1,650	796	425	429
<i>Avandia products</i>	576	302	151	123	1,123	589	294	240
<i>Avandia</i>	365	210	62	93	712	410	121	181
<i>Avandamet</i>	186	75	85	26	363	146	166	51
<i>Bonviva/Boniva</i>	161	105	51	5	314	205	99	10
Anti-bacterials	1,032	124	456	452	2,012	242	889	881
<i>Augmentin</i>	428	34	198	196	835	67	386	382
<i>Altabax</i>	11	10	1	-	21	19	2	-
Oncology and emesis	358	179	119	60	698	349	232	117
<i>Hycamtin</i>	99	56	35	8	193	109	68	16
<i>Zofran</i>	93	13	47	33	181	25	92	64
<i>Tykerb</i>	67	33	25	9	131	64	49	18
Vaccines	1,743	451	799	493	3,399	880	1,558	961
<i>Hepatitis</i>	480	201	189	90	936	392	369	175
<i>Infanrix/Pediarix</i>	488	156	264	68	952	304	515	133
<i>Fluarix, FluLaval</i>	149	63	57	29	291	123	111	57
<i>Flu-prepandemic</i>	49	-	49	-	96	-	96	-
<i>Cervarix</i>	70	-	59	11	137	-	115	22
<i>Rotarix</i>	101	4	30	67	197	8	58	131
<i>Boostrix</i>	53	27	19	7	103	52	37	14
Other	700	13	218	469	1,365	25	425	915
	14,578	6,368	4,657	3,553	28,427	12,419	9,080	6,928

Pharmaceutical turnover includes co-promotion income. US dollar amounts shown above are a convenience translation of the sterling amounts.

Turnover

Consumer Healthcare

Three months ended 30th September 2008

	Total £m	USA £m	Europe £m	ROW £m	Total \$m	USA \$m	Europe \$m	ROW \$m
Over-the-counter medicines	476	155	142	179	893	292	266	335
<i>Panadol franchise</i>	82	-	20	62	154	-	38	116
Smoking cessation products	83	60	13	10	157	114	24	19
<i>Tums</i>	21	18	-	3	39	33	-	6
Cold sore franchise	22	10	8	4	41	19	14	8
<i>Breathe Right</i>	19	13	4	2	35	24	7	4
<i>alli</i>	18	18	-	-	34	34	-	-
Oral healthcare	310	54	174	82	581	101	326	154
<i>Aquafresh franchise</i>	116	20	72	24	218	37	135	46
<i>Sensodyne franchise</i>	90	17	43	30	169	32	81	56
Dental healthcare	68	15	27	26	127	28	51	48
Nutritional healthcare	208	-	127	81	390	-	238	152
<i>Lucozade</i>	100	-	89	11	187	-	167	20
<i>Horlicks</i>	53	-	5	48	99	-	9	90
<i>Ribena</i>	44	-	33	11	83	-	62	21
	994	209	443	342	1,864	393	830	641

Turnover

Consumer Healthcare

Nine months ended 30th September 2008

	Total £m	USA £m	Europe £m	ROW £m	Total \$m	USA \$m	Europe \$m	ROW \$m
Over-the counter medicines	1,356	423	420	513	2,644	825	819	1,000
<i>Panadol franchise</i>	240	-	56	184	468	-	109	359
Smoking cessation products	206	145	42	19	402	283	82	37
<i>Tums</i>	64	55	-	9	125	107	-	18
Cold sore franchise	61	26	27	8	119	51	52	16
<i>Breathe Right</i>	54	32	14	8	105	62	27	16
<i>alli</i>	45	43	-	2	88	84	-	4
Oral healthcare	897	154	502	241	1,749	300	979	470
<i>Aquafresh franchise</i>	330	58	202	70	644	113	394	137
<i>Sensodyne franchise</i>	263	47	127	89	513	92	248	173
Dental healthcare	194	44	78	72	378	86	152	140
Nutritional healthcare	611	-	371	240	1,192	-	724	468
<i>Lucozade</i>	293	-	260	33	571	-	507	64
<i>Horlicks</i>	157	-	16	141	306	-	31	275
<i>Ribena</i>	124	-	94	30	242	-	183	59
	2,864	577	1,293	994	5,585	1,125	2,522	1,938

Balance sheet

	30th September 2008 £m	30th September 2008 \$m
ASSETS		
Non-current assets		
Property, plant and equipment	8,395	14,943
Goodwill	1,747	3,110
Other intangible assets	4,944	8,800
Investments in associates and joint ventures	445	792
Other investments	454	808
Deferred tax assets	2,439	4,342
Derivative financial instruments	17	30
Other non-current assets	465	828
Total non-current assets	18,906	33,653
Current assets		
Inventories	3,515	6,257
Current tax recoverable	50	89
Trade and other receivables	5,483	9,760
Derivative financial instruments	349	621
Liquid investments	401	714
Cash and cash equivalents	5,148	9,163
Assets held for sale	8	14
Total current assets	14,954	26,618
TOTAL ASSETS	33,860	60,271
LIABILITIES		
Current liabilities		
Short-term borrowings	(1,387)	(2,469)
Trade and other payables	(5,143)	(9,154)
Derivative financial instruments	(195)	(347)
Current tax payable	(1,058)	(1,883)
Short-term provisions	(1,015)	(1,807)
Total current liabilities	(8,798)	(15,660)
Non-current liabilities		
Long-term borrowings	(12,801)	(22,786)
Deferred tax liabilities	(652)	(1,161)
Pensions and other post-employment benefits	(2,312)	(4,115)
Other provisions	(1,129)	(2,010)
Other non-current liabilities	(371)	(660)
Total non-current liabilities	(17,265)	(30,732)
TOTAL LIABILITIES	(26,063)	(46,392)
NET ASSETS	7,797	13,879
EQUITY		
Share capital	1,423	2,533
Share premium account	1,322	2,353
Retained earnings	4,099	7,296
Other reserves	642	1,143
Shareholders' equity	7,486	13,325
Minority interests	311	554
TOTAL EQUITY	7,797	13,879

US dollar amounts shown above are a convenience transaction of the sterling amounts using the period end rate of £1/\$1.78.